Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics

In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The revie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Theranostics 2020, Vol.10 (1), p.437-461
Hauptverfasser:	Velikyan, Irina, Eriksson, Olof
Format:	Artikel
Sprache:	eng
Schlagworte:	Biodistribution Cancer Diabetes Diabetes Mellitus - diagnostic imaging Diabetes Mellitus - therapy Dosimetry Drug dosages Exendin-4 GLP-1 Glucagon Glucagon-Like Peptide-1 Receptor - antagonists & inhibitors Glucose Humans Insulin insulinoma Ligands Metabolism Neoplasms - diagnostic imaging Neoplasms - therapy Neuroendocrine tumors Pancreas Peptides PET Plasma Precision Medicine - methods Radiopharmaceuticals - therapeutic use Review SPECT Transplants & implants
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In the light of theranostics/radiotheranostics and prospective of personalized medicine in diabetes and oncology, this review presents prior and current advances in the development of radiolabeled imaging and radiotherapeutic exendin-based agents targeting glucagon-like peptide-1 receptor. The review covers chemistry, preclinical, and clinical evaluation. Such critical aspects as structure-activity-relationship, stability, physiological potency, kidney uptake, and dosimetry are discussed.
ISSN:	1838-7640 1838-7640
DOI:	10.7150/thno.38366